View Clinical Trial (Medical Research Study)
DNA Chip Based Prognosis of Lung Cancer
| City: |
|
Buffalo |
| State: |
|
New York |
| Zip Code: |
|
14263 |
| Conditions: |
|
Carcinoma, Non-Small-Cell Lung |
| Purpose: |
|
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis
Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous
and large cell lung cancer).
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. A histological diagnosis of primary NSCLC stage Ia
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC
stage Ib-IV after surgery.
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to
concurrent illnesses.
|
| NCT ID: |
|
NCT00973427 |
| Primary Contact: |
|
Study Chair
Steen Knudsen, PhD
Medical Prognosis Institute (MPI)
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Buffalo, New York 14263
United States
Sai Yendamuri, MD
Phone: 716-239-0532
Email: Sai.Yendamuri@Roswellpark.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|